This invention relates to a series of arylsubstituted piperazines, of Formula I
1
pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the &agr;-1a adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this and other disease.
本发明涉及一系列芳基取代的
哌嗪类化合物,其式为 I
1
含有这些化合物的药物组合物以及用于制造这些化合物的中间体。本发明的化合物可选择性地抑制与&agr;-1a
肾上腺素能受体的结合,该受体与良性前列腺增生症有关。因此,本发明化合物可用于治疗良性前列腺增生症和其他疾病。